Ultragenyx Pharmaceutical Inc. Stock
A loss of -1.510% shows a downward development for Ultragenyx Pharmaceutical Inc..
The stock is an absolute favorite of our community with 26 Buy predictions and no Sell predictions.
Based on the current price of 22.77 € the target price of 50 € shows a potential of 119.59% for Ultragenyx Pharmaceutical Inc. which would more than double the current price.
Pros and Cons of Ultragenyx Pharmaceutical Inc. in the next few years
Pros
?
C******** o* t** e**********
?
S********** s********
?
M***** P*******
Cons
?
W********* I********* f** t** n*** y****
?
B****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Ultragenyx Pharmaceutical Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. | -1.510% | -3.271% | -21.914% | -5.125% | 35.536% | -31.000% | -70.994% |
| Ligand Pharmaceuticals | -0.800% | 0.787% | -5.882% | 93.939% | 54.217% | 306.349% | 173.329% |
| United Therapeutics | -0.210% | -7.275% | -6.269% | 61.171% | 1.123% | 98.850% | 151.221% |
| Ionis Pharmaceuticals Inc. | 0.930% | 1.290% | 2.869% | 34.457% | -27.192% | 35.265% | 46.999% |
Comments
Ultragenyx Pharmaceutical (RARE) had its "buy" rating reaffirmed by HC Wainwright. They now have a $50.00 price target on the stock.
Show more
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical (RARE) had its price target lowered by Wells Fargo & Company from $47.00 to $45.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical (RARE) had its price target lowered by Guggenheim from $43.00 to $35.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat
News
Ultragenyx Pharmaceutical Q2 Earnings Call Highlights
Key Points
- Interested in Ultragenyx Pharmaceutical Inc.? Here are five stocks we like better.
- Ultragenyx reported record Q2 revenue of $214 million, led by Crysvita’s $156 million contribution
What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year
On May 14, 2026, Krensavage Asset Management disclosed it bought 241,245 shares of Ultragenyx Pharmaceutical (NASDAQ:RARE), an estimated $5.43 million trade based on quarterly average pricing.
